Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.59 |
| ▸ | SCN5A known ✓ | Q14524 | 2/20 | 0.59 |
| ▸ | SCN9A known ✓ | Q15858 | 2/20 | 0.59 |
| ▸ | SCN4A known ✓ | P35499 | 10/20 | 0.56 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.56 |
| ▸ | SCN8A known ✓ | Q9UQD0 | 2/20 | 0.56 |
| ▸ | KCNK3 known ✓ | O14649 | 1/20 | 0.56 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.56 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.56 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.56 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.56 |
| ▸ | SCN7A known ✓ | Q01118 | 1/20 | 0.56 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.56 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.56 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.56 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.56 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.56 |
| ▸ | SCN11A known ✓ | Q9UI33 | 1/20 | 0.56 |
| ▸ | SCN10A known ✓ | Q9Y5Y9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8816944 | 1.00 | LMNA (0.59) | LMNASCN1ASCN5ASCN9ASCN4A | |
| SCHEMBL5684024 | 0.98 | SCN4A (0.58) | LMNASCN1ASCN5ASCN9ASCN4A | |
| SCHEMBL8815305 | 0.98 | SCN4A (0.58) | LMNASCN1ASCN5ASCN9ASCN4A | |
| SCHEMBL8816903 | 0.98 | SCN4A (0.58) | LMNASCN1ASCN5ASCN9ASCN4A | |
| Cadaverine Tartrate SCHEMBL8816907 | 0.85 | NPC1 (0.48) | LMNASCN1ASCN5ASCN9ASCN4A | |
| Cadaverine Tartrate SCHEMBL8816909 | 0.85 | NPC1 (0.48) | LMNASCN1ASCN5ASCN9ASCN4A | |
| SCHEMBL19668683 | 0.85 | KCNH2 (0.58) | LMNASCN1ASCN5ASCN9ASCN4A | |
| SCHEMBL8819029 | 0.85 | KCNH2 (0.58) | LMNASCN1ASCN5ASCN9ASCN4A | |
| Hydrochloric Acid SCHEMBL11657872 | 0.82 | LMNA (0.62) | LMNASCN1ASCN5ASCN9ASCN4A | |
| SCHEMBL19668687 | 0.82 | KCNH2 (0.55) | LMNASCN1ASCN5ASCN9ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5688830-A | SODIUM CHANNEL BLOCKERS AS ANALGESICS | SYNTEX (U.S.A.) INC. (US) | 1997-11-18 | — | — | US | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207422-A1 | NERVE TARGETING PEPTIDE CONJUGATES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-20240091387-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | ALUME BIOSCIENCES INC (US) | 2024-03-21 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| CN-111246873-B | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnosis and therapy delivery | 加利福尼亚大学董事会 | 2024-03-01 | — | — | CN | disclosed |
| US-11802138-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostic and therapeutic delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-31 | — | — | US | disclosed |
| US-20100273864-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010121023-A2 | PEPTIDES AND APTAMERS FOR TARGETING OF NEURON OR NERVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010074992-A2 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010062413-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010011605-A2 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100015263-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-5688830-A | SODIUM CHANNEL BLOCKERS AS ANALGESICS | SYNTEX (U.S.A.) INC. (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1997027169-A1 | (2-DIMETHYLPHENOXY-1-METHYLETHYL) ETHYLAMINE | F.HOFFMANN-LA ROCHE AG (CH) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015263-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, MYOC, S100B | SCN1A 892/4885SCN5A 1627/4885SCN9A 1647/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | SCN1A 1450/4885SCN5A 1850/4885SCN9A 1130/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | SCN1A 2987/4885SCN5A 3162/4885SCN9A 4062/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | SCN1A 3065/4885SCN5A 3960/4885SCN9A 3201/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | SCN1A 2987/4885SCN5A 3162/4885SCN9A 4062/4885 |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, TLR3, STING1 | SCN1A 3690/4885SCN5A 4268/4885SCN9A 4081/4885 |
| US-20100273864-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, MYOC, S100B | SCN1A 892/4885SCN5A 1627/4885SCN9A 1647/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | SCN1A 2987/4885SCN5A 3162/4885SCN9A 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.